Portage Biotech Inc., of Toronto, said its Biohaven unit started dosing subjects in the first study testing the pharmacokinetics and safety of BHV-4157. Read More
Synaffix BV, of Amsterdam, said preclinical studies showed that its platform technologies, Glycoconnect and Hydraspace, generated antibody drug conjugates (ADCs) with improved therapeutic index in comparison to the ADCs Kadcyla (trastuzumab emtansine, Genentech Inc./Roche Group) and Adcetris (brentuximab vedotin, Seattle Genetics Inc.), approved by the FDA to treat HER2-positive breast cancer and multiple lymphoma indications, respectively. Read More
Ablynx NV, of Ghent, Belgium, said an additional 39,818 common shares have been issued in exchange for €160,489 (US$176,860) as the result of the exercise of warrants. Read More
Viracor-Ibt Laboratories Inc., of Lee's Summit, Mo., received emergency use authorization from the FDA for its Zika virus real-time RT-PCR assay. Read More
DUBLIN – In the smoke-and-mirrors world of drug pricing in Europe, Ireland is claiming a little victory on foot of a new drug pricing agreement with the pharmaceutical industry which will help to keep a lid on rising drug prices between now and 2020. Read More
In another promising sign for the gene therapy space, shares of Audentes Therapeutics Inc. received an encouraging welcome on Wall Street Wednesday after the San Francisco-based firm priced a $75 million IPO, offering 5 million shares at $15 each, the midpoint of its proposed range. Read More
DURBAN, South Africa – "When people learn that tuberculosis is airborne, that it kills millions of people, that drug resistance is spreading, watch their reaction – they do not think that TB is boring anymore," Jose Luis Castro, executive director of the International Union Against Tuberculosis and Lung Disease, told the audience at the 2016 international AIDS conference. Read More
LONDON – Precision Ocular Ltd. closed a £15.5 million (US$20.4 million) series A funding that will enable it to take the first of new generation of low-dose, slow-release retinal drugs from preclinical research and into the clinic. Read More
Zafgen Inc. scrapped plans to develop its lead candidate, beloranib, after deciding the road forward would be too long and costly, based on FDA feedback, following two patient deaths in its phase III bestPWS trial in Prader-Willi syndrome (PWS). Read More
